SOURCE: Bollinger Report

May 25, 2012 09:00 ET

A Forward Look, the Year Ahead - Featured Research on Baidu.com, Inc. (ADR) and Medivation, Inc.

HONG KONG--(Marketwire - May 25, 2012) - Today, www.BollingerReport.com introduced featured coverage of Baidu.com, Inc. (ADR) (NASDAQ: BIDU) and Medivation, Inc. (NASDAQ: MDVN). Full research reports are available to readers at: www.BollingerReport.com/index.php?sm1=BIDU&sm2=MDVN.

Economic fundamentals leading into 2012 have set a generally positive pace with GDP growth likely to pick up through the coming year. However, there are several important caveats to note as the world economy continues to face headwinds and risks weigh to the downside. Positive outlooks are conditional on fiscal policy in payroll taxes and unemployment insurance benefits and upon the easing of the European debt situation. A repeat of volatility experience in 2011 is likely in 2012, as perceptions about the strength of the U.S. economy and the euro zone will vary over time as events unfold.

Despite the current situation, our team continues to identify high momentum situations with growth potential -- there remains strong opportunity within careful discretion.

Bollinger Report screened and selected Baidu.com, Inc. (ADR) for its current position within the technology industry. Baidu, Inc. (Baidu) is a Chinese-language Internet search provider. Baidu serves three types of online participants, which include users, customers and Baidu union members. The Company offers a Chinese-language search platform on its Website Baidu.com. A copy of this report featuring Baidu.com, Inc. (ADR) (NASDAQ: BIDU) is available at: www.BollingerReport.com/index.php?sm1=BIDU.

Bollinger Report is featuring Medivation, Inc. for its changing role within the healthcare industry. Medivation, Inc. is a biopharmaceutical company focused on the rapid development of small molecule drugs to treat serious diseases for which there are limited treatment options. Together with its collaboration partner Astellas Pharma Inc. (Astellas), the Company is developing MDV3100 for multiple stages of advanced prostate cancer. To download researches and analysis on Medivation, Inc. (NASDAQ: MDVN) we welcome investors to visit: www.BollingerReport.com/index.php?sm2=MDVN.

About Bollinger Report
Bollinger Report has come to be known among its peers as a trusted source of information for both investors and technical traders. Our online content is continually updated, bringing fresh new researches and analyses to the investment community. John Bollinger and BollingerBands.com are not affiliated with BollingerReport.com and do not endorse the service or any of the recommendations made by the service.

Contact Information